Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Int J Hematol. 2020 Sep;112(3):431-432.
doi: 10.1007/s12185-020-02932-8.
1 Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
2 Department of Hematology, National Kyushu Medical Center, Fukuoka, Japan.
3 Department of Hematology, Harasanshin Hospital, Fukuoka, Japan.
4 Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
5 Department of Hematology, Kurume University Hospital, Kurume, Japan.
6 Department of Hematology, Japan Community Health Care Organization Kyushu Hospital, Kita-Kyushu, Japan.
7 Department of Hematology, Toranomon Hospital, Tokyo, Japan.
8 Department of Hematology, Matsuyama Red Cross Hospital, Ehime, Japan.
9 Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. toshmiya@intmed1.med.kyushu-u.ac.jp.
In the original publication of the article, the "CNS involvement" in the last row under the column "Total N=50" has been published incorrectly. The correct Table 1 is given in this correction.